Share Price and Basic Stock Data
Last Updated: August 1, 2025, 3:38 pm
PEG Ratio | -1.16 |
---|
Quick Insight
Evoq Remedies Ltd currently trades at ₹3.72, with a market capitalization of ₹9.26 crore, reflecting a high price-to-earnings (P/E) ratio of 103, suggesting overvaluation relative to its earnings of ₹0.09 crore. The company's return on equity (ROE) stands at a mere 0.26%, while return on capital employed (ROCE) is slightly better at 0.35%, indicating inefficient capital utilization. With an operating profit margin (OPM) of -5.10%, the firm is struggling to generate profits from its revenues. Notably, it has no borrowings, which is a positive aspect, but a cash conversion cycle (CCC) of 121.72 days raises concerns about liquidity. Given these factors, investors should approach Evoq Remedies with caution, as its high valuation metrics do not align well with its current financial performance.
Competitors of Evoq Remedies Ltd
Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
---|---|---|---|---|---|---|---|---|---|
Lactose (India) Ltd | 140 Cr. | 99.1 | 247/84.3 | 27.1 | 41.7 | 0.00 % | 12.9 % | 9.75 % | 10.0 |
MPS Pharmaa Ltd | 4.72 Cr. | 2.47 | 4.33/2.47 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
Gujarat Terce Laboratories Ltd | 36.6 Cr. | 49.4 | 94.9/45.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
Gujarat Inject (Kerala) Ltd | 31.7 Cr. | 21.6 | 29.1/13.1 | 31.1 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
Industry Average | 19,015.83 Cr | 1,190.81 | 53.48 | 193.55 | 0.32% | 16.63% | 15.27% | 6.18 |
Quarterly Result
Metric | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|
Sales | 2.76 | 4.93 | 11.85 | 15.79 | 4.60 | 3.90 | 0.15 | 0.00 | 11.76 |
Expenses | 1.71 | 4.20 | 11.12 | 15.48 | 8.64 | 3.83 | 1.87 | 1.63 | 12.36 |
Operating Profit | 1.05 | 0.73 | 0.73 | 0.31 | -4.04 | 0.07 | -1.72 | -1.63 | -0.60 |
OPM % | 38.04% | 14.81% | 6.16% | 1.96% | -87.83% | 1.79% | -1,146.67% | -5.10% | |
Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 6.02 | 0.00 | 2.26 | 0.01 | 2.40 |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
Profit before tax | 1.05 | 0.73 | 0.73 | 0.31 | 1.98 | 0.07 | 0.54 | -1.62 | 1.76 |
Tax % | 22.86% | 0.00% | 50.68% | 0.00% | 33.84% | 28.57% | 29.63% | 0.00% | 2.27% |
Net Profit | 0.81 | 0.73 | 0.36 | 0.31 | 1.31 | 0.05 | 0.38 | -1.62 | 1.71 |
EPS in Rs | 810.00 | 730.00 | 0.26 | 0.23 | 0.96 | 0.04 | 0.28 | -0.65 | 0.69 |
Last Updated: May 31, 2025, 6:06 am
Below is a detailed analysis of the quarterly data for Evoq Remedies Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 11.76 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Sep 2024) to 11.76 Cr., marking an increase of 11.76 Cr..
- For Expenses, as of Mar 2025, the value is 12.36 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.63 Cr. (Sep 2024) to 12.36 Cr., marking an increase of 10.73 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.60 Cr.. The value appears strong and on an upward trend. It has increased from -1.63 Cr. (Sep 2024) to -0.60 Cr., marking an increase of 1.03 Cr..
- For OPM %, as of Mar 2025, the value is -5.10%. The value appears to be declining and may need further review. It has decreased from 0.00% (Sep 2024) to -5.10%, marking a decrease of 5.10%.
- For Other Income, as of Mar 2025, the value is 2.40 Cr.. The value appears strong and on an upward trend. It has increased from 0.01 Cr. (Sep 2024) to 2.40 Cr., marking an increase of 2.39 Cr..
- For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Depreciation, as of Mar 2025, the value is 0.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Sep 2024) to 0.04 Cr., marking an increase of 0.04 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.76 Cr.. The value appears strong and on an upward trend. It has increased from -1.62 Cr. (Sep 2024) to 1.76 Cr., marking an increase of 3.38 Cr..
- For Tax %, as of Mar 2025, the value is 2.27%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Sep 2024) to 2.27%, marking an increase of 2.27%.
- For Net Profit, as of Mar 2025, the value is 1.71 Cr.. The value appears strong and on an upward trend. It has increased from -1.62 Cr. (Sep 2024) to 1.71 Cr., marking an increase of 3.33 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.69. The value appears strong and on an upward trend. It has increased from -0.65 (Sep 2024) to 0.69, marking an increase of 1.34.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: May 15, 2025, 3:35 am
Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|
Sales | 3.25 | 9.07 | 10.02 | 16.78 | 20.39 | 4.05 | 11.76 |
Expenses | 3.23 | 9.07 | 9.07 | 15.32 | 24.12 | 5.69 | 13.99 |
Operating Profit | 0.02 | 0.00 | 0.95 | 1.46 | -3.73 | -1.64 | -2.23 |
OPM % | 0.62% | 0.00% | 9.48% | 8.70% | -18.29% | -40.49% | -18.96% |
Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 6.02 | 2.26 | 2.41 |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.05 |
Profit before tax | 0.02 | 0.00 | 0.95 | 1.46 | 2.29 | 0.61 | 0.13 |
Tax % | 0.00% | 25.26% | 25.34% | 29.26% | 26.23% | 30.77% | |
Net Profit | 0.01 | 0.00 | 0.72 | 1.09 | 1.62 | 0.45 | 0.09 |
EPS in Rs | 10.00 | 0.00 | 720.00 | 0.80 | 1.19 | 0.33 | 0.04 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
Year | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
---|---|---|---|---|---|
YoY Net Profit Growth (%) | -100.00% | 51.39% | 48.62% | -72.22% | -80.00% |
Change in YoY Net Profit Growth (%) | 0.00% | 151.39% | -2.77% | -120.85% | -7.78% |
Evoq Remedies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2019-2020 to 2024-2025.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 5% |
3 Years: | -11% |
TTM: | 190% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -56% |
TTM: | -80% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -35% |
1 Year: | -58% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 4% |
3 Years: | 3% |
Last Year: | 0% |
Last Updated: Unknown
Balance Sheet
Last Updated: July 25, 2025, 1:19 pm
Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|
Equity Capital | 0.01 | 0.01 | 0.01 | 13.60 | 13.60 | 13.60 | 24.90 |
Reserves | 0.01 | 0.01 | 0.73 | 9.57 | 11.19 | 11.64 | 19.64 |
Borrowings | 0.00 | 0.01 | 0.00 | 8.16 | 9.58 | 4.24 | 0.00 |
Other Liabilities | 2.12 | 5.62 | 7.30 | 2.00 | 0.53 | 7.39 | 5.47 |
Total Liabilities | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 | 50.01 |
Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.22 |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Assets | 2.14 | 5.65 | 8.04 | 33.33 | 34.89 | 36.86 | 49.79 |
Total Assets | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 | 50.01 |
Below is a detailed analysis of the balance sheet data for Evoq Remedies Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 24.90 Cr.. The value appears strong and on an upward trend. It has increased from 13.60 Cr. (Mar 2024) to 24.90 Cr., marking an increase of 11.30 Cr..
- For Reserves, as of Mar 2025, the value is 19.64 Cr.. The value appears strong and on an upward trend. It has increased from 11.64 Cr. (Mar 2024) to 19.64 Cr., marking an increase of 8.00 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 4.24 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 4.24 Cr..
- For Other Liabilities, as of Mar 2025, the value is 5.47 Cr.. The value appears to be improving (decreasing). It has decreased from 7.39 Cr. (Mar 2024) to 5.47 Cr., marking a decrease of 1.92 Cr..
- For Total Liabilities, as of Mar 2025, the value is 50.01 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 36.87 Cr. (Mar 2024) to 50.01 Cr., marking an increase of 13.14 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.22 Cr.. The value appears strong and on an upward trend. It has increased from 0.01 Cr. (Mar 2024) to 0.22 Cr., marking an increase of 0.21 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 49.79 Cr.. The value appears strong and on an upward trend. It has increased from 36.86 Cr. (Mar 2024) to 49.79 Cr., marking an increase of 12.93 Cr..
- For Total Assets, as of Mar 2025, the value is 50.01 Cr.. The value appears strong and on an upward trend. It has increased from 36.87 Cr. (Mar 2024) to 50.01 Cr., marking an increase of 13.14 Cr..
Notably, the Reserves (19.64 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|
Free Cash Flow | 0.02 | -0.01 | 0.95 | -6.70 | -13.31 | -5.88 | -2.23 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
No data available for the Financial Efficiency data table.
This stock is not held by any mutual fund.
Key Financial Ratios
Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
---|---|---|---|---|---|
FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Basic EPS (Rs.) | 0.04 | 0.03 | 1.19 | 1.09 | 10.05 |
Diluted EPS (Rs.) | 0.04 | 0.03 | 1.19 | 1.09 | 10.05 |
Cash EPS (Rs.) | 0.05 | 0.33 | 1.19 | 0.80 | 713.80 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 17.89 | 18.56 | 18.22 | 17.03 | 736.40 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 17.89 | 18.56 | 18.22 | 17.03 | 736.40 |
Revenue From Operations / Share (Rs.) | 4.72 | 2.98 | 14.99 | 12.34 | 10024.80 |
PBDIT / Share (Rs.) | 0.07 | 0.45 | 1.68 | 1.08 | 953.90 |
PBIT / Share (Rs.) | 0.05 | 0.44 | 1.68 | 1.08 | 953.90 |
PBT / Share (Rs.) | 0.05 | 0.44 | 1.68 | 1.07 | 953.90 |
Net Profit / Share (Rs.) | 0.03 | 0.33 | 1.19 | 0.80 | 713.80 |
PBDIT Margin (%) | 1.50 | 15.26 | 11.22 | 8.71 | 9.51 |
PBIT Margin (%) | 1.09 | 15.08 | 11.21 | 8.71 | 9.51 |
PBT Margin (%) | 1.09 | 15.08 | 11.20 | 8.68 | 9.51 |
Net Profit Margin (%) | 0.75 | 11.16 | 7.94 | 6.50 | 7.12 |
Return on Networth / Equity (%) | 0.19 | 1.79 | 6.53 | 4.71 | 96.93 |
Return on Capital Employeed (%) | 0.28 | 2.42 | 9.22 | 6.31 | 128.45 |
Return On Assets (%) | 0.17 | 1.22 | 4.64 | 3.27 | 8.87 |
Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Total Debt / Equity (X) | 0.00 | 0.16 | 0.38 | 0.35 | 0.01 |
Asset Turnover Ratio (%) | 0.27 | 0.11 | 0.59 | 0.81 | 1.46 |
Current Ratio (X) | 9.10 | 3.17 | 3.45 | 3.28 | 1.10 |
Quick Ratio (X) | 8.69 | 2.90 | 3.25 | 3.20 | 1.08 |
Interest Coverage Ratio (X) | 0.00 | 0.00 | 1761.31 | 316.78 | 0.00 |
Interest Coverage Ratio (Post Tax) (X) | 0.00 | 0.00 | 1246.62 | 237.30 | 0.00 |
Enterprise Value (Cr.) | 6.16 | 15.91 | 27.09 | 35.80 | 0.00 |
EV / Net Operating Revenue (X) | 0.52 | 3.92 | 1.33 | 2.13 | 0.00 |
EV / EBITDA (X) | 34.78 | 25.71 | 11.83 | 24.47 | 0.00 |
MarketCap / Net Operating Revenue (X) | 0.54 | 2.91 | 0.86 | 1.83 | 0.00 |
Price / BV (X) | 0.14 | 0.46 | 0.71 | 1.33 | 0.00 |
Price / Net Operating Revenue (X) | 0.54 | 2.91 | 0.86 | 1.83 | 0.00 |
EarningsYield | 0.01 | 0.03 | 0.09 | 0.03 | 0.00 |
After reviewing the key financial ratios for Evoq Remedies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 3. It has decreased from 0.33 (Mar 24) to 0.05, marking a decrease of 0.28.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 17.89. It has decreased from 18.56 (Mar 24) to 17.89, marking a decrease of 0.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 17.89. It has decreased from 18.56 (Mar 24) to 17.89, marking a decrease of 0.67.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 4.72. It has increased from 2.98 (Mar 24) to 4.72, marking an increase of 1.74.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 2. It has decreased from 0.45 (Mar 24) to 0.07, marking a decrease of 0.38.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.05. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.05, marking a decrease of 0.39.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.05. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.05, marking a decrease of 0.39.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 2. It has decreased from 0.33 (Mar 24) to 0.03, marking a decrease of 0.30.
- For PBDIT Margin (%), as of Mar 25, the value is 1.50. This value is below the healthy minimum of 10. It has decreased from 15.26 (Mar 24) to 1.50, marking a decrease of 13.76.
- For PBIT Margin (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 10. It has decreased from 15.08 (Mar 24) to 1.09, marking a decrease of 13.99.
- For PBT Margin (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 10. It has decreased from 15.08 (Mar 24) to 1.09, marking a decrease of 13.99.
- For Net Profit Margin (%), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 5. It has decreased from 11.16 (Mar 24) to 0.75, marking a decrease of 10.41.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 15. It has decreased from 1.79 (Mar 24) to 0.19, marking a decrease of 1.60.
- For Return on Capital Employeed (%), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 10. It has decreased from 2.42 (Mar 24) to 0.28, marking a decrease of 2.14.
- For Return On Assets (%), as of Mar 25, the value is 0.17. This value is below the healthy minimum of 5. It has decreased from 1.22 (Mar 24) to 0.17, marking a decrease of 1.05.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.16 (Mar 24) to 0.00, marking a decrease of 0.16.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.27. It has increased from 0.11 (Mar 24) to 0.27, marking an increase of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 9.10. This value exceeds the healthy maximum of 3. It has increased from 3.17 (Mar 24) to 9.10, marking an increase of 5.93.
- For Quick Ratio (X), as of Mar 25, the value is 8.69. This value exceeds the healthy maximum of 2. It has increased from 2.90 (Mar 24) to 8.69, marking an increase of 5.79.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6.16. It has decreased from 15.91 (Mar 24) to 6.16, marking a decrease of 9.75.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 1. It has decreased from 3.92 (Mar 24) to 0.52, marking a decrease of 3.40.
- For EV / EBITDA (X), as of Mar 25, the value is 34.78. This value exceeds the healthy maximum of 15. It has increased from 25.71 (Mar 24) to 34.78, marking an increase of 9.07.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.54. This value is below the healthy minimum of 1. It has decreased from 2.91 (Mar 24) to 0.54, marking a decrease of 2.37.
- For Price / BV (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 1. It has decreased from 0.46 (Mar 24) to 0.14, marking a decrease of 0.32.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.54. This value is below the healthy minimum of 1. It has decreased from 2.91 (Mar 24) to 0.54, marking a decrease of 2.37.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Evoq Remedies Ltd:
- Net Profit Margin: 0.75%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.28% (Industry Average ROCE: 16.63%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.19% (Industry Average ROE: 15.27%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 8.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 99.6 (Industry average Stock P/E: 53.48)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.75%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Pharmaceuticals | A-1106, Empire Business Hub, Near AUDA Water Tank, Ahmedabad Gujarat 380060 | info@evoqremedies.com http://www.evoqremedies.com |
Management | |
---|---|
Name | Position Held |
Mr. Bhumishth Patel | Managing Director |
Mr. Narendrakumar Patel | Non Executive Director |
Mr. Pranav Vajani | Independent Director |
Mr. Harsh Kothari | Independent Director |
FAQ
What is the intrinsic value of Evoq Remedies Ltd?
Evoq Remedies Ltd's intrinsic value (as of 05 August 2025) is ₹3.78 which is 5.00% higher the current market price of ₹3.60, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 8.96 Cr. market cap, FY2025-2026 high/low of 9.64/2.11, reserves of 19.64 Cr, and liabilities of 50.01 Cr.
What is the Market Cap of Evoq Remedies Ltd?
The Market Cap of Evoq Remedies Ltd is 8.96 Cr..
What is the current Stock Price of Evoq Remedies Ltd as on 05 August 2025?
The current stock price of Evoq Remedies Ltd as on 05 August 2025 is 3.60.
What is the High / Low of Evoq Remedies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Evoq Remedies Ltd stocks is ₹9.64/2.11.
What is the Stock P/E of Evoq Remedies Ltd?
The Stock P/E of Evoq Remedies Ltd is 99.6.
What is the Book Value of Evoq Remedies Ltd?
The Book Value of Evoq Remedies Ltd is 17.9.
What is the Dividend Yield of Evoq Remedies Ltd?
The Dividend Yield of Evoq Remedies Ltd is 0.00 %.
What is the ROCE of Evoq Remedies Ltd?
The ROCE of Evoq Remedies Ltd is 0.35 %.
What is the ROE of Evoq Remedies Ltd?
The ROE of Evoq Remedies Ltd is 0.26 %.
What is the Face Value of Evoq Remedies Ltd?
The Face Value of Evoq Remedies Ltd is 10.0.